|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Henry Ford Health System |
|---|---|
| Information provided by: | Henry Ford Health System |
| ClinicalTrials.gov Identifier: | NCT00720980 |
Purpose
Granuloma annulare is a benign, usually self-limiting, cutaneous dermatosis, which typically presents as asymptomatic, flesh-colored or red papules, frequently arranged in an annular pattern on the distal extremities. Although localized granuloma annulare is most commonly observed, a generalized or disseminated form can occur. The etiology of granuloma annulare is unknown, however, multiple inciting factors have been proposed. The purpose of the investigators is to review the outcomes of treatment of granuloma annulare (GA) resistant to standard regimens that resolved after a 3-months treatment course of monthly rifampin, ofloxacin, and minocycline (ROM) therapy, successfully used to treat paucibacillary leprosy, a disease with clinical and histopathologic similarity to GA.
| Condition |
|---|
|
Granuloma Annulare |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Retrospective |
| Official Title: | Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy |
| Enrollment: | 6 |
| Study Start Date: | May 2008 |
| Study Completion Date: | July 2008 |
| Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
We will document the regimen treatment each patient has had and then review the following from the patient's chart to target our specific aims as outlined above.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
The investigators reported 6 cases of resistant GA that resolved after a 3-month treatment course of monthly rifampin, ofloxacin, and minocycline (ROM) therapy. ROM therapy has been successfully used to treat patients with paucibacillary leprosy, which has morphologic and histologic similarities to GA.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Michigan | |
| Henry Ford Medical Center | |
| Detroit, Michigan, United States, 48202 | |
| Principal Investigator: | Iltefat H Hamzavi, MD | Henry Ford Health System |
More Information
| Responsible Party: | Iltefat H. Hamzavi, MD, Henry Ford Health System |
| ClinicalTrials.gov Identifier: | NCT00720980 History of Changes |
| Other Study ID Numbers: | IRB5074 |
| Study First Received: | July 21, 2008 |
| Last Updated: | July 21, 2008 |
| Health Authority: | United States: Institutional Review Board |
|
granuloma annulare, ROM |
|
Granuloma Granuloma Annulare Lymphoproliferative Disorders Lymphatic Diseases Pathologic Processes Necrobiotic Disorders Collagen Diseases Connective Tissue Diseases Skin Diseases Minocycline Ofloxacin Rifampin |
Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Urinary Renal Agents Antibiotics, Antitubercular Antitubercular Agents Leprostatic Agents |